Myriad Genetics Inc (MYGN)

Pretax margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before tax but after interest (EBT)	US$ in thousands	-123,500	-262,200	-140,600	-57,100	-283,700
Revenue	US$ in thousands	837,600	753,200	678,400	690,600	557,000
Pretax margin		-14.74%	-34.81%	-20.73%	-8.27%	-50.93%

December 31, 2024 calculation

Pretax margin = EBT ÷ Revenue
= $-123,500K ÷ $837,600K
= -14.74%

The pretax margin for Myriad Genetics Inc has shown significant fluctuations over the past five years. In December 2020, the company reported a concerning pretax margin of -50.93%, indicating that its expenses exceeded its gross profit by a substantial margin. However, in the following years, there was some improvement in the pretax margin, with the figure improving to -8.27% by December 2021.

Despite this initial progress, the pretax margin deteriorated in December 2022 to -20.73%, before experiencing a further decline to -34.81% by December 2023. This suggests that the company faced challenges in controlling its operating expenses relative to its revenue during these periods.

The most recent data point, in December 2024, shows a partial recovery in the pretax margin to -14.74%. While this improvement indicates efforts to enhance operational efficiency, the company still has room for further enhancement to achieve profitability.

Overall, Myriad Genetics Inc's pretax margin performance reflects a volatile trend, highlighting the company's need to focus on cost management and revenue generation strategies to enhance its profitability in the future.